CY2550B1 - - Google Patents

Info

Publication number
CY2550B1
CY2550B1 CY0600004A CY0600004A CY2550B1 CY 2550 B1 CY2550 B1 CY 2550B1 CY 0600004 A CY0600004 A CY 0600004A CY 0600004 A CY0600004 A CY 0600004A CY 2550 B1 CY2550 B1 CY 2550B1
Authority
CY
Cyprus
Application number
CY0600004A
Inventor
Guido Bold
Joerg Frei
Peter Traxler
Karl-Heinz Altmann
Helmut Mett
David Raymond Stover
Jeanette Wood
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY2550B1 publication Critical patent/CY2550B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY0600004A 1997-02-13 2006-02-13 CY2550B1 (cg-RX-API-DMAC10.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH31597 1997-02-13

Publications (1)

Publication Number Publication Date
CY2550B1 true CY2550B1 (cg-RX-API-DMAC10.html) 2008-07-02

Family

ID=4184213

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0600004A CY2550B1 (cg-RX-API-DMAC10.html) 1997-02-13 2006-02-13

Country Status (32)

Country Link
US (3) US6258812B1 (cg-RX-API-DMAC10.html)
EP (1) EP0970070B1 (cg-RX-API-DMAC10.html)
JP (1) JP3544675B2 (cg-RX-API-DMAC10.html)
KR (1) KR100441362B1 (cg-RX-API-DMAC10.html)
CN (1) CN1251097B (cg-RX-API-DMAC10.html)
AR (1) AR011135A1 (cg-RX-API-DMAC10.html)
AT (1) ATE278686T1 (cg-RX-API-DMAC10.html)
AU (1) AU731852B2 (cg-RX-API-DMAC10.html)
BR (1) BR9807685B1 (cg-RX-API-DMAC10.html)
CA (1) CA2281721C (cg-RX-API-DMAC10.html)
CO (1) CO4950519A1 (cg-RX-API-DMAC10.html)
CY (1) CY2550B1 (cg-RX-API-DMAC10.html)
CZ (1) CZ297534B6 (cg-RX-API-DMAC10.html)
DE (1) DE69826841T2 (cg-RX-API-DMAC10.html)
DK (1) DK0970070T3 (cg-RX-API-DMAC10.html)
ES (1) ES2234097T3 (cg-RX-API-DMAC10.html)
HU (1) HU227972B1 (cg-RX-API-DMAC10.html)
ID (1) ID23698A (cg-RX-API-DMAC10.html)
IL (1) IL131273A0 (cg-RX-API-DMAC10.html)
MY (1) MY128645A (cg-RX-API-DMAC10.html)
NO (1) NO317367B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ337064A (cg-RX-API-DMAC10.html)
PE (1) PE52499A1 (cg-RX-API-DMAC10.html)
PL (1) PL197371B1 (cg-RX-API-DMAC10.html)
PT (1) PT970070E (cg-RX-API-DMAC10.html)
RU (1) RU2207132C2 (cg-RX-API-DMAC10.html)
SI (1) SI0970070T1 (cg-RX-API-DMAC10.html)
SK (1) SK285757B6 (cg-RX-API-DMAC10.html)
TR (1) TR199901953T2 (cg-RX-API-DMAC10.html)
TW (1) TWI250151B (cg-RX-API-DMAC10.html)
WO (1) WO1998035958A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA981155B (cg-RX-API-DMAC10.html)

Families Citing this family (310)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EP0929526B1 (en) 1996-09-25 2005-07-27 AstraZeneca AB Qinoline derivatives inhibiting the effect of growth factors such as vegf
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
ES2289791T3 (es) 1997-08-22 2008-02-01 Astrazeneca Ab Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
CA2339961C (en) * 1998-08-11 2009-01-20 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
PT1105136E (pt) * 1998-08-13 2007-12-03 Novartis Ag Método para tratar doenças oculares neovasculares
AU766081B2 (en) * 1999-03-30 2003-10-09 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
US6271233B1 (en) 1999-08-10 2001-08-07 Ciba Vision Corporation Method for treating ocular neovascular diseases
US6689883B1 (en) 1999-09-28 2004-02-10 Bayer Pharmaceuticals Corporation Substituted pyridines and pyridazines with angiogenesis inhibiting activity
DOP2000000070A (es) * 1999-09-28 2002-02-28 Bayer Healthcare Llc Piridinas y piridacinas sustituidas con actividad de inhibición de angiogénesis
PL203782B1 (pl) 1999-11-05 2009-11-30 Astrazeneca Ab Pochodne chinazoliny,sposoby ich wytwarzania,ich kompozycje farmaceutyczne oraz ich zastosowania
DE19963607B4 (de) * 1999-12-23 2005-12-15 Schering Ag Verfahren zur Herstellung von 4-(Heteroaryl-methyl) halogen-1(2H)-phthalazinonen
US6706731B2 (en) 2000-02-09 2004-03-16 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase
US7087608B2 (en) 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
CA2403365A1 (en) 2000-04-07 2001-10-18 Astrazeneca Ab Quinazoline compounds
US7977333B2 (en) 2000-04-20 2011-07-12 Bayer Healthcare Llc Substituted pyridines and pyridazines with angiogenesis inhibiting activity
EP1166799A1 (en) * 2000-06-28 2002-01-02 Schering Aktiengesellschaft Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II)
EP1166798A1 (en) * 2000-06-23 2002-01-02 Schering Aktiengesellschaft Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/ Tie receptor function and their use
MEP13708A (en) * 2000-06-23 2010-06-10 Bayer Schering Pharma Ag Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
NZ523987A (en) * 2000-08-09 2004-10-29 Astrazeneca Ab Indole, azaindole and indazole derivatives having VEGF inhibiting activity
US6903101B1 (en) * 2000-08-10 2005-06-07 Bayer Pharmaceuticals Corporation Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity
EP1415987B1 (en) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
AU9578901A (en) * 2000-10-30 2002-05-15 Kudos Pharm Ltd Phthalazinone derivatives
CA2427184A1 (en) * 2000-11-22 2002-05-30 Novartis Ag Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
US7814641B2 (en) 2001-01-09 2010-10-19 Black & Decker Inc. Method of forming a power tool
US7096566B2 (en) 2001-01-09 2006-08-29 Black & Decker Inc. Method for making an encapsulated coil structure
EP1363627A2 (en) 2001-02-19 2003-11-26 Novartis AG Treatment of solid tumours with rapamycin derivatives
GB0111078D0 (en) 2001-05-04 2001-06-27 Novartis Ag Organic compounds
US20040167134A1 (en) 2001-05-16 2004-08-26 Christian Bruns Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US20030073692A1 (en) * 2001-08-07 2003-04-17 Pharmacia & Upjohn S.P.A. Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
RU2320344C2 (ru) * 2001-09-12 2008-03-27 Новартис Аг Применение 4-пиридилметилфталазинов для лечения рака
SI1427420T1 (sl) * 2001-09-12 2006-12-31 Novartis Ag Uporaba kombinacije, ki vsebuje 4-piridilmetilftalazine za zdravljenje raka
ES2320922T3 (es) * 2001-09-12 2009-05-29 Novartis Ag Uso de 4-piridilmetilftalazinas para el tratamiento de cancer renal.
US20040266779A1 (en) * 2001-09-27 2004-12-30 Anderson Kenneth C. Use of c-kit inhibitors for the treatment of myeloma
MXPA04003878A (es) * 2001-10-25 2004-07-08 Novartis Ag Combinaciones que comprenden un inhibidor selectivo de cicloxigenasa-2.
MXPA04005561A (es) * 2001-12-21 2004-12-06 Bayer Pharmaceuticals Corp Terapias de combinacion anti-angiogenesis que comprenden derivados de piridazina o piridina.
RU2316554C2 (ru) 2001-12-27 2008-02-10 Тереванс, Инк. Производные индолина, используемые как ингибиторы протеинкиназы
US20030171375A1 (en) * 2002-02-13 2003-09-11 Brazzell Romulus Kimbro Method for treating ocular neovascular diseases
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
US20050209237A1 (en) * 2002-04-30 2005-09-22 Brazzell Romulus K Method for decreasing capillary permeability in the retina
AU2003240655B2 (en) 2002-05-16 2007-09-06 Novartis Ag Use of EDG receptor binding agents in cancer
EP1545527A1 (en) * 2002-06-28 2005-06-29 Novartis AG Combination comprising a vasculostatic compound and an alkylating agent for the treatmemt of a tumor
US7195876B2 (en) * 2002-08-09 2007-03-27 Theravance, Inc. Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
US20060128716A1 (en) * 2002-09-24 2006-06-15 Dugan Margaret H Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
US20060148810A1 (en) * 2002-10-10 2006-07-06 Frank Giles Treatment of amm
US7268137B2 (en) * 2002-11-07 2007-09-11 Campochiaro Peter A Ocular therapy
JP2006507319A (ja) * 2002-11-12 2006-03-02 ノバルティス アクチエンゲゼルシャフト 中皮腫の処置
US7094785B1 (en) 2002-12-18 2006-08-22 Cornell Research Foundation, Inc. Method of treating polycythemia vera
EP1581228A1 (en) * 2002-12-20 2005-10-05 Dana-Farber Cancer Institute, Inc. Treatment of von hippel lindau disease
EP1738752A1 (en) * 2002-12-27 2007-01-03 Schering Aktiengesellschaft Pharmaceutical combinations comprising cis-retine acid
EP2527326B1 (en) 2003-03-07 2014-10-08 Santen Pharmaceutical Co., Ltd Novel compounds having 4-pyridylalkylthio group as substituent
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20040242886A1 (en) * 2003-04-30 2004-12-02 Sandeep Gupta Monocyclic diazodioxide based Bcl-2 protein antagonists related applications
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
EP2644195A1 (en) 2003-05-19 2013-10-02 Irm Llc Immunosuppressant Compounds and Compositions
CN103755807A (zh) 2003-07-18 2014-04-30 安姆根有限公司 肝细胞生长因子的特异性结合物
WO2005044788A1 (ja) 2003-11-11 2005-05-19 Eisai Co., Ltd. ウレア誘導体およびその製造方法
KR101153647B1 (ko) 2003-11-18 2012-06-18 노파르티스 아게 Ｋｉｔ 돌연변이형에 대한 저해제
US20050171182A1 (en) * 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
NZ548949A (en) 2004-02-17 2009-09-25 Santen Pharmaceutical Co Ltd Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein
EP1568368A1 (en) * 2004-02-26 2005-08-31 Schering Aktiengesellschaft Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor
FR2868780B1 (fr) 2004-04-13 2008-10-17 Sanofi Synthelabo Derives de la 1-amino-phthalazine, leur preparation et leur application en therapeutique
EP1765313A2 (en) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
EP1797877A4 (en) 2004-09-13 2010-12-15 Eisai Co Ltd JOINT USE OF A SULFONAMIDE-BASED COMPOUND AND AN ANGIOGENESIS INHIBITOR
PE20060664A1 (es) * 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
AU2005283422C1 (en) 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
ES2325344B1 (es) * 2004-11-02 2010-06-09 Univ Madrid Autonoma Inhibidores de angiogenesis multifuncionales y multivalentes.
CA2587642C (en) 2004-11-30 2013-04-09 Amgen Inc. Substituted heterocycles and methods of use
DE602006016564D1 (de) * 2005-03-03 2010-10-14 Santen Pharmaceutical Co Ltd Neue cyclische verbindung mit chinolylalkylthiogruppe
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
EP1864977B1 (en) 2005-03-31 2015-07-29 Santen Pharmaceutical Co., Ltd. Novel cyclic compound having pyrimidinylalkylthio group
GT200600147A (es) * 2005-04-13 2006-11-24 Uso de inhibidores de receptor de factor de crecimiento endotelial vascular para el tratamiento de canceres gastrointestinal, genitourinario, linfoide y pulmonar
CN101171013A (zh) 2005-05-02 2008-04-30 诺瓦提斯公司 嘧啶基氨基苯甲酰胺衍生物用于治疗全身性肥大细胞增多症的应用
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP1731154A1 (en) * 2005-06-07 2006-12-13 Schering Aktiengesellschaft Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl)|4-(4-pyridylmethyl)pht halazin-1-yl| and salts thereof
EP1731153A1 (en) * 2005-06-07 2006-12-13 Schering Aktiengesellschaft Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)¬4-(4-pyridylmethyl)phthalazin-1-yl| and salts thereof
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
GB0517205D0 (en) * 2005-08-22 2005-09-28 Novartis Ag Organic compounds
WO2007030582A2 (en) 2005-09-09 2007-03-15 Bristol-Myers Squibb Company Acyclic ikur inhibitors
KR20080054417A (ko) 2005-09-27 2008-06-17 노파르티스 아게 카르복시아민 화합물 및 ｈｄａｃ 의존성 질환의 치료에있어서의 그의 용도
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
ES2481671T3 (es) 2005-11-21 2014-07-31 Novartis Ag Inhibidores de mTOR en el tratamiento de tumores endocrinos
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
US20080108664A1 (en) * 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
WO2007092178A1 (en) 2006-02-10 2007-08-16 Amgen Inc. Hydrate forms of amg706
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
MX2008012715A (es) 2006-04-05 2008-10-14 Novartis Ag Combinaciones de agentes terapeuticos para el tratamiento de cancer.
AR060358A1 (es) * 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
US8777120B2 (en) * 2006-04-15 2014-07-15 International Business Machines Corporation Hydronic radiant flooring heating system
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
MX2008014292A (es) 2006-05-09 2008-11-18 Novartis Ag Combinacion que comprende un quelante de hierro y un agente anti-neoplastico, y uso de la misma.
EP2021338A1 (en) 2006-05-09 2009-02-11 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
WO2007136103A1 (ja) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
GB0610925D0 (en) * 2006-06-02 2006-07-12 Novartis Ag Use of vascular endothelial growth factor receptor inhibitors for the treatment of cancer
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
AR062207A1 (es) 2006-08-04 2008-10-22 Takeda Pharmaceutical Derivados de imidazopiridazina inhibidores de quinasas utiles para prevenir y/o tratar el cancer.
WO2008026748A1 (en) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
EP2081933B1 (en) 2006-09-29 2011-03-23 Novartis AG Pyrazolopyrimidines as pi3k lipid kinase inhibitors
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
CA2672438A1 (en) 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
EP2118069B1 (en) 2007-01-09 2014-01-01 Amgen Inc. Bis-aryl amide derivatives useful for the treatment of cancer
KR101475540B1 (ko) 2007-01-29 2014-12-22 산텐 세이야꾸 가부시키가이샤 혈관 신생 저해 활성을 갖는 신규 옥사디아졸 유도체 및 티아디아졸 유도체
EP2119707B1 (en) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
CA2677651A1 (en) 2007-02-15 2008-08-21 Novartis Ag Combinations of therapeutic agents for treating cancer
MX2009008531A (es) 2007-02-16 2009-08-26 Amgen Inc Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
TW200904816A (en) 2007-06-05 2009-02-01 Takeda Pharmaceutical Fused heterocycle derivatives and use thereof
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
SI2188313T1 (en) 2007-08-21 2018-04-30 Amgen, Inc. HUMAN C-FMS ANTIGEN TRANSFER PROTEIN
US8324395B2 (en) 2007-08-23 2012-12-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
CN101116664B (zh) * 2007-08-28 2010-05-19 山东省科学院生物研究所 化合物1-(4-氯苯胺基)-4-(4-甲基吡啶基)-2,3-二氮杂萘的应用
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
UY31545A1 (es) 2007-12-20 2009-08-03 Nuevos derivados de 2-carboxamida cianoaminourea, sus sales y profarmacos farmacéuticamente aceptables, procesos de preparacion y aplicaciones
ES2519474T3 (es) 2008-03-26 2014-11-07 Novartis Ag Inhibidores de las desacetilasas B basados en hidroxamato
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20110190322A1 (en) 2008-08-14 2011-08-04 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
ES2704986T3 (es) 2008-10-16 2019-03-21 Celator Pharmaceuticals Inc Combinaciones de una camptotecina liposomal soluble en agua con cetuximab o bevacizumab
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
AU2009327405A1 (en) 2008-12-18 2011-06-30 Novartis Ag New polymorphic form of 1- (4- { l- [ (E) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic
HRP20131106T1 (hr) 2008-12-18 2013-12-20 Novartis Ag Hemifumaratna sol od 1-[4-[1-(4-cikloheksil-3-trifluorometil-benziloksiimino)-etil]-2-etil-benzil]-azetidin-3-karboksilne kiseline
CN102256941A (zh) 2008-12-18 2011-11-23 诺瓦提斯公司 新的盐
KR20110103968A (ko) 2008-12-23 2011-09-21 베링거 인겔하임 인터내셔날 게엠베하 유기 화합물의 염 형태
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
TWI466672B (zh) 2009-01-29 2015-01-01 Boehringer Ingelheim Int 小兒科病人糖尿病之治療
US20110281917A1 (en) 2009-01-29 2011-11-17 Darrin Stuart Substituted Benzimidazoles for the Treatment of Astrocytomas
NZ594044A (en) 2009-02-13 2014-08-29 Boehringer Ingelheim Int Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
US8530492B2 (en) 2009-04-17 2013-09-10 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
KR101360725B1 (ko) 2009-06-26 2014-02-07 노파르티스 아게 Ｃｙｐ17의 억제제로서의 1,3-이치환된 이미다졸리딘-2-온 유도체
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
AU2010284254B2 (en) 2009-08-17 2015-09-17 Intellikine, Llc Heterocyclic compounds and uses thereof
ES2564797T3 (es) 2009-08-19 2016-03-29 Eisai R&D Management Co., Ltd. Composición farmacéutica con contenido en un derivado de quinolina
EA201200318A1 (ru) 2009-08-20 2012-09-28 Новартис Аг Гетероциклические оксимы
JP2013503129A (ja) 2009-08-26 2013-01-31 ノバルティス アーゲー テトラ−置換ヘテロアリール化合物ならびにｍｄｍ２および／またはｍｄｍ４モジュレーターとしてのそれらの使用
AU2010294209A1 (en) 2009-09-10 2012-03-29 Irm Llc Ether derivatives of bicyclic heteroaryls
CA2776296C (en) 2009-10-02 2017-11-07 Boehringer Ingelheim International Gmbh Therapeutic uses of pharmaceutical compositions
EP2496575B1 (en) 2009-11-04 2014-04-30 Novartis AG Heterocyclic sulfonamide derivatives useful as mek inhibitors
CN102712648A (zh) 2009-11-25 2012-10-03 诺瓦提斯公司 双环杂芳基的与苯稠合的6元含氧杂环衍生物
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
ES2484171T3 (es) 2009-12-08 2014-08-11 Novartis Ag Derivados de sulfonamidas heterocíclicas
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
JP2013532149A (ja) 2010-06-17 2013-08-15 ノバルティス アーゲー ピペリジニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
CN102947274A (zh) 2010-06-17 2013-02-27 诺瓦提斯公司 联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
WO2011161217A2 (en) 2010-06-23 2011-12-29 Palacký University in Olomouc Targeting of vegfr2
MX2012014247A (es) 2010-06-24 2013-01-18 Boehringer Ingelheim Int Terapia para la diabetes.
RU2560683C2 (ru) 2010-06-25 2015-08-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство, задействующее соединения с ингибирующим эффектом к киназам в комбинации
JP2013539962A (ja) 2010-07-09 2013-10-31 ジェネンテック， インコーポレイテッド 抗ニューロピリン抗体及び使用方法
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
US8946260B2 (en) 2010-09-16 2015-02-03 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP2640384A1 (en) 2010-11-18 2013-09-25 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
AU2011329681A1 (en) 2010-11-18 2013-05-30 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment based on hypoxic status
PL2670753T3 (pl) 2011-01-31 2017-05-31 Novartis Ag Nowe pochodne heterocykliczne
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
CN103492390A (zh) 2011-03-08 2014-01-01 诺瓦提斯公司 氟苯基双环杂芳基化合物
MY161199A (en) 2011-03-23 2017-04-14 Amgen Inc Fused tricyclic dual inhibitors of cdk 4/6 and flt3
MX2013009931A (es) 2011-04-18 2013-10-01 Eisai R&D Man Co Ltd Agentes terapeuticos contra tumores.
WO2012149413A1 (en) 2011-04-28 2012-11-01 Novartis Ag 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
ES2705950T3 (es) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
KR20140034898A (ko) 2011-06-09 2014-03-20 노파르티스 아게 헤테로시클릭 술폰아미드 유도체
AU2012270310B2 (en) * 2011-06-16 2016-01-28 Katholieke Universiteit Leuven K.U. Leuven R & D 1,3-Di-oxo-indene derivative, pharmaceutically acceptable salt or optical isomer thereof, preparation method thereof, and pharmaceutical composition containing same as an antiviral, active ingredient
EP2721007B1 (en) 2011-06-20 2015-04-29 Novartis AG Cyclohexyl isoquinolinone compounds
US8859535B2 (en) 2011-06-20 2014-10-14 Novartis Ag Hydroxy substituted isoquinolinone derivatives
ES2934843T3 (es) 2011-07-15 2023-02-27 Boehringer Ingelheim Int Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
WO2013025939A2 (en) 2011-08-16 2013-02-21 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
US12194002B2 (en) 2011-08-17 2025-01-14 Dennis Brown Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dibromodulcitol
EA026655B1 (ru) 2011-09-15 2017-05-31 Новартис Аг 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
PT2771342T (pt) 2011-10-28 2016-08-17 Novartis Ag Derivados de purina e o seu uso no tratamento de doença
EP2785717B1 (en) 2011-11-29 2016-01-13 Novartis AG Pyrazolopyrrolidine compounds
EA201491268A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами по связыванию
US20140357633A1 (en) 2011-12-23 2014-12-04 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
KR20140104047A (ko) 2011-12-23 2014-08-27 노파르티스 아게 Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
EA201491265A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
EA201491259A1 (ru) 2011-12-23 2014-11-28 Новартис Аг Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами связывания
US20130172244A1 (en) 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US20150297604A1 (en) 2012-04-03 2015-10-22 Novartis Ag Combination Products with Tyrosine Kinase Inhibitors and their Use
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
US10213432B2 (en) 2012-05-16 2019-02-26 Novartis Ag Dosage regimen for a PI-3 kinase inhibitor
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2013175417A1 (en) 2012-05-24 2013-11-28 Novartis Ag Pyrrolopyrrolidinone compounds
WO2013174768A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
CA2880896C (en) 2012-06-26 2021-11-16 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
US9505749B2 (en) 2012-08-29 2016-11-29 Amgen Inc. Quinazolinone compounds and derivatives thereof
SI3882244T1 (sl) 2012-12-14 2025-07-31 Korea Research Institute Of Chemical Technology Spojina, farmacevtsko sprejemljiva sol ali optični izomer le-te, postopek za njeno pripravo in farmacevtski sestavek za preprečevanje ali zdravljenje virusnih bolezni, ki jo vsebuje kot učinkovino
WO2014098176A1 (ja) 2012-12-21 2014-06-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体のアモルファス及びその製造方法
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
CN105246482A (zh) 2013-03-15 2016-01-13 因特利凯有限责任公司 激酶抑制剂的组合及其用途
AU2014230096C1 (en) 2013-03-15 2019-08-29 Boehringer Ingelheim International Gmbh Use of linagliptin in cardio- and renoprotective antidiabetic therapy
WO2014155268A2 (en) 2013-03-25 2014-10-02 Novartis Ag Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
US11491154B2 (en) 2013-04-08 2022-11-08 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
RU2658601C2 (ru) 2013-05-14 2018-06-21 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Биомаркер для прогнозирования и оценки чувствительности субъектов с раком эндометрия к соединениям ленватиниба
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
MX378409B (es) 2013-12-06 2025-03-10 Novartis Ag Regimen de dosificacion para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa.
JP6526789B2 (ja) 2014-07-31 2019-06-05 ノバルティス アーゲー 組み合わせ療法
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
ES2887474T3 (es) 2015-01-08 2021-12-22 Univ Leland Stanford Junior Factores y células que proporcionan inducción de hueso, médula ósea y cartílago
US20180093956A1 (en) * 2015-02-06 2018-04-05 Abbvie Inc. Substituted phthalazines
RS65049B1 (sr) 2015-02-25 2024-02-29 Eisai R&D Man Co Ltd Metoda za suzbijanje gorčine derivata kinolina
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
HK1247089A1 (zh) 2015-03-10 2018-09-21 Aduro Biotech, Inc. 用於活化“干扰素基因刺激物”依赖性信号传导的组合物和方法
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
ES2887426T3 (es) 2015-08-20 2021-12-22 Eisai R&D Man Co Ltd Lenvatinib combinado con etopósido e ifosfamida para su uso en el tratamiento de un tumor
JP2018532750A (ja) 2015-11-02 2018-11-08 ノバルティス アーゲー ホスファチジルイノシトール３−キナーゼ阻害剤の投薬レジメン
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
KR20230150408A (ko) 2016-12-22 2023-10-30 암젠 인크 폐암, 췌장암 또는 대장암을 치료하기 위한 kras g12c 억제제로서의 벤즈이소티아졸, 이소티아졸로[3,4-b]피리딘, 퀴나졸린, 프탈라진, 피리도[2,3-d]피리다진 및 피리도[2,3-d]피리미딘 유도체
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
AU2018329920B2 (en) 2017-09-08 2022-12-01 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
US12023353B2 (en) 2017-10-18 2024-07-02 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Methods and compounds for improved immune cell therapy
JP7021356B2 (ja) 2017-12-21 2022-02-16 ヘフェイ インスティテューツ オブ フィジカル サイエンス， チャイニーズ アカデミー オブ サイエンシーズ ピリミジン誘導体系キナーゼ阻害剤類
MA52501A (fr) 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
AU2019262599B2 (en) 2018-05-04 2023-10-12 Amgen Inc. KRAS G12C inhibitors and methods of using the same
MA52564A (fr) 2018-05-10 2021-03-17 Amgen Inc Inhibiteurs de kras g12c pour le traitement du cancer
EP3802535B1 (en) 2018-06-01 2022-12-14 Amgen, Inc Kras g12c inhibitors and methods of using the same
AU2019284472B2 (en) 2018-06-11 2024-05-30 Amgen Inc. KRAS G12C inhibitors for treating cancer
US11285156B2 (en) 2018-06-12 2022-03-29 Amgen Inc. Substituted piperazines as KRAS G12C inhibitors
KR20210035227A (ko) 2018-07-17 2021-03-31 베링거 인겔하임 인터내셔날 게엠베하 심장 안전성 및 신장 안전성 항당뇨 치료법
AU2019304485C1 (en) 2018-07-17 2025-05-01 Boehringer Ingelheim International Gmbh Cardiosafe antidiabetic therapy
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
MX2021005700A (es) 2018-11-19 2021-07-07 Amgen Inc Inhibidores de kras g12c y metodos de uso de los mismos.
KR102875569B1 (ko) 2018-12-20 2025-10-23 암젠 인크 Kif18a 억제제
CA3123042A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
MX419368B (es) 2018-12-20 2025-01-14 Amgen Inc Heteroarilamidas utiles como inhibidores de kif18a
EP3898592B1 (en) 2018-12-20 2024-10-09 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
AU2020232242A1 (en) 2019-03-01 2021-09-09 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
CN113727758A (zh) 2019-03-01 2021-11-30 锐新医药公司 双环杂环基化合物及其用途
JP2022532379A (ja) * 2019-05-14 2022-07-14 ザ スクリプス リサーチ インスティテュート 神経変性および代謝障害の処置のための化合物
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
CA3140392A1 (en) 2019-05-21 2020-11-26 Amgen Inc. Solid state forms
AU2020324406A1 (en) 2019-08-02 2022-03-17 Amgen Inc. KIF18A inhibitors
CA3147276A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
ES3051917T3 (en) 2019-08-02 2025-12-30 Amgen Inc Kif18a inhibitors
US20220281843A1 (en) 2019-08-02 2022-09-08 Amgen Inc. Kif18a inhibitors
AU2020369569A1 (en) 2019-10-24 2022-04-14 Amgen Inc. Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer
WO2021091982A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
BR112022008535A2 (pt) 2019-11-04 2022-08-09 Revolution Medicines Inc Composto, composição farmacêutica, métodos para tratar câncer e um distúrbio relativo à proteína ras
CN120699039A (zh) 2019-11-04 2025-09-26 锐新医药公司 Ras抑制剂
US20210139517A1 (en) 2019-11-08 2021-05-13 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
EP4058465A1 (en) 2019-11-14 2022-09-21 Cohbar Inc. Cxcr4 antagonist peptides
AU2020383535A1 (en) 2019-11-14 2022-05-05 Amgen Inc. Improved synthesis of KRAS G12C inhibitor compound
TW202532412A (zh) 2019-11-14 2025-08-16 美商安進公司 Kras g12c抑制劑化合物之改善的合成
JP2023505100A (ja) 2019-11-27 2023-02-08 レボリューション メディシンズ インコーポレイテッド 共有ｒａｓ阻害剤及びその使用
JP2023509701A (ja) 2020-01-07 2023-03-09 レヴォリューション・メディスンズ，インコーポレイテッド Ｓｈｐ２阻害剤投薬およびがんを処置する方法
CA3176618A1 (en) 2020-04-20 2021-10-28 Novartis Ag Antiviral 1,3-di-oxo-indene compounds
TWI832045B (zh) 2020-04-20 2024-02-11 瑞士商諾華公司 抗病毒性1,3-二氧代茚化合物
KR20230042600A (ko) 2020-06-18 2023-03-28 레볼루션 메디슨즈, 인크. Ras 억제제에 대한 획득된 저항성을 지연, 예방, 및 치료하는 방법
CA3187757A1 (en) 2020-09-03 2022-03-24 Ethan AHLER Use of sos1 inhibitors to treat malignancies with shp2 mutations
MX2023003060A (es) 2020-09-15 2023-04-05 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
JP2024501280A (ja) 2020-12-22 2024-01-11 キル・レガー・セラピューティクス・インコーポレーテッド Ｓｏｓ１阻害剤およびその使用
AU2022212106A1 (en) * 2021-01-28 2023-08-17 University Of Florida Research Foundation, Incorporated Compounds and use thereof for treatment of neurodegenerative, degenerative and metabolic disorders
CN118561952A (zh) 2021-05-05 2024-08-30 锐新医药公司 Ras抑制剂
CR20230558A (es) 2021-05-05 2024-01-24 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cáncer
CN117500811A (zh) 2021-05-05 2024-02-02 锐新医药公司 共价ras抑制剂及其用途
US20250059182A1 (en) * 2021-06-21 2025-02-20 Mirati Therapeutics, Inc. Sos1 inhibitors
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
EP4448526A1 (en) 2021-12-17 2024-10-23 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023121413A1 (ko) * 2021-12-24 2023-06-29 제일약품주식회사 신규한 바이사이클릭 헤테로사이클릴 화합물 및 이의 용도
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
CN118829629A (zh) 2022-03-07 2024-10-22 美国安进公司 用于制备4-甲基-2-丙-2-基-吡啶-3-甲腈的方法
JP2025510572A (ja) 2022-03-08 2025-04-15 レボリューション メディシンズ インコーポレイテッド 免疫不応性肺癌を治療するための方法
CN119998298A (zh) 2022-06-10 2025-05-13 锐新医药公司 大环ras抑制剂
EP4601644A1 (en) 2022-10-14 2025-08-20 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
AR132338A1 (es) 2023-04-07 2025-06-18 Revolution Medicines Inc Inhibidores de ras
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式
TW202448897A (zh) 2023-04-14 2024-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2960504A (en) 1957-05-07 1960-11-15 Ciba Pharm Prod Inc 1-hydrazino, 4-pyridyl methyl-phthalazines
BE567431A (cg-RX-API-DMAC10.html) * 1957-05-07
GB1094044A (en) 1965-07-12 1967-12-06 Vantorex Ltd Phthalazine derivatives
DE1695994A1 (de) 1967-05-05 1971-05-19 Vantorex Ltd Verfahren zur Herstellung von Phthalazinen
GB1293565A (en) 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd １―（３―ピリジルメチル）フタラジン誘導体
EP0600831A1 (de) * 1992-11-27 1994-06-08 Ciba-Geigy Ag Phthalazinonderivate
CN1058390C (zh) * 1993-10-15 2000-11-15 伊莱利利公司 苯并噻吩类化合物的用途
AU705229B2 (en) * 1994-08-09 1999-05-20 Eisai R&D Management Co., Ltd. Fused pyridazine compound
ATE203534T1 (de) * 1996-01-15 2001-08-15 Janssen Pharmaceutica Nv Angiogenesis hemmende pyridazinamine
DE19617863A1 (de) 1996-04-23 1997-10-30 Schering Ag Phthalazinderivate, deren Herstellung und Verwendung als Arzneimittel
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
ITMI981670A1 (it) * 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodiesterasi 4
PT1105136E (pt) * 1998-08-13 2007-12-03 Novartis Ag Método para tratar doenças oculares neovasculares

Also Published As

Publication number Publication date
JP2001508800A (ja) 2001-07-03
BR9807685B1 (pt) 2013-05-21
SI0970070T1 (en) 2005-04-30
MY128645A (en) 2007-02-28
ID23698A (id) 2000-05-11
CZ297534B6 (cs) 2007-01-03
PL335113A1 (en) 2000-04-10
ZA981155B (en) 1998-08-13
AR011135A1 (es) 2000-08-02
EP0970070A1 (en) 2000-01-12
PL197371B1 (pl) 2008-03-31
NO993888D0 (no) 1999-08-12
AU6621898A (en) 1998-09-08
TR199901953T2 (xx) 1999-10-21
NO317367B1 (no) 2004-10-18
SK285757B6 (sk) 2007-07-06
BR9807685A (pt) 2000-03-21
CZ285399A3 (cs) 1999-11-17
US6514974B2 (en) 2003-02-04
CN1251097A (zh) 2000-04-19
US20030191129A1 (en) 2003-10-09
KR100441362B1 (ko) 2004-07-23
HUP0001046A2 (hu) 2001-04-28
CN1251097B (zh) 2011-10-19
US6258812B1 (en) 2001-07-10
EP0970070B1 (en) 2004-10-06
PE52499A1 (es) 1999-06-10
CA2281721C (en) 2008-01-22
DE69826841T2 (de) 2006-02-09
PT970070E (pt) 2005-02-28
DK0970070T3 (da) 2005-02-14
KR20000071049A (ko) 2000-11-25
HUP0001046A3 (en) 2002-04-29
US20020091261A1 (en) 2002-07-11
HU227972B1 (en) 2012-07-30
SK109699A3 (en) 2000-03-13
ATE278686T1 (de) 2004-10-15
CA2281721A1 (en) 1998-08-20
CO4950519A1 (es) 2000-09-01
NO993888L (no) 1999-10-11
JP3544675B2 (ja) 2004-07-21
TWI250151B (en) 2006-03-01
US6710047B2 (en) 2004-03-23
NZ337064A (en) 2001-04-27
ES2234097T3 (es) 2005-06-16
IL131273A0 (en) 2001-01-28
RU2207132C2 (ru) 2003-06-27
DE69826841D1 (de) 2004-11-11
AU731852B2 (en) 2001-04-05
WO1998035958A1 (en) 1998-08-20

Similar Documents

Publication Publication Date Title
BE2018C032I2 (cg-RX-API-DMAC10.html)
IN191207B (cg-RX-API-DMAC10.html)
IN191602B (cg-RX-API-DMAC10.html)
ITMI971349A0 (cg-RX-API-DMAC10.html)
CH0944937H2 (cg-RX-API-DMAC10.html)
IN189723B (cg-RX-API-DMAC10.html)
ITMI971468A0 (cg-RX-API-DMAC10.html)
IN188653B (cg-RX-API-DMAC10.html)
IN189826B (cg-RX-API-DMAC10.html)
IN186651B (cg-RX-API-DMAC10.html)
ITMI971171A0 (cg-RX-API-DMAC10.html)
ITMI971522A0 (cg-RX-API-DMAC10.html)
ITTO970395A0 (cg-RX-API-DMAC10.html)
BE2013C047I2 (cg-RX-API-DMAC10.html)
ITMI971199A0 (cg-RX-API-DMAC10.html)
IN188659B (cg-RX-API-DMAC10.html)
IN186140B (cg-RX-API-DMAC10.html)
IN192604B (cg-RX-API-DMAC10.html)
IN183786B (cg-RX-API-DMAC10.html)
IN186499B (cg-RX-API-DMAC10.html)
IN188459B (cg-RX-API-DMAC10.html)
ITTV970066A0 (cg-RX-API-DMAC10.html)
IN191154B (cg-RX-API-DMAC10.html)
BR9701757A (cg-RX-API-DMAC10.html)
IN183698B (cg-RX-API-DMAC10.html)